{
    "nctId": "NCT01377363",
    "briefTitle": "Evaluation of Degree of Conversion of HER2 Receptor Between Primary Breast Cancer and Metastasis",
    "officialTitle": "Evaluation of Degree of Conversion of HER2 Receptor Between Primary Breast Cancer and Metastasis",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 236,
    "primaryOutcomeMeasure": "Evaluation of degree of conversion of human epidermal growth factor receptor 2 (HER2) receptor between primary breast cancer and metastases",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients who have given their written informed consent to participate in the study.\n* Women over 18 years.\n* Breast cancer locally recurrent or metastatic at first relapse or after successive progressions.\n* Patient has to have available a sample of the primary tumor in paraffin.\n* Patients who are planning for the next 6 weeks, the biopsy (fine needle aspiration / drainage of fluid cavities, open biopsy, core biopsy) of locally recurrent or metastatic lesion \\[local relapse in the chest wall, nodal , cutaneous or subcutaneous metastases, peripheral lymph nodes and other soft tissues accessible, bone metastases, visceral metastases (lung, liver, brain, etc..) or pleural effusion / ascites / pericardial / cerebrospinal\\] according to clinical practice center.\n\nExclusion Criteria:\n\n* Patients with cognitive impairment that might impede a proper understanding of the written informed consent, according to medical criteria.\n* Ipsilateral breast local relapses or contralateral breast away.\n* Patients diagnosed with a second neoplasm, with the exception of cervical carcinoma in situ and non-melanoma skin carcinoma treated properly.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}